Potential Oral ACTH Inhibitor for Cushing’s Disease Entering Phase 1 Trial

Potential Oral ACTH Inhibitor for Cushing’s Disease Entering Phase 1 Trial

286292

Potential Oral ACTH Inhibitor for Cushing’s Disease Entering Phase 1 Trial

Crinetics Pharmaceuticals is launching a Phase 1 clinical trial to evaluate the safety and tolerability of oral CRN04894, an inhibitor of adrenocorticotropic hormone (ACTH) activity, in healthy volunteers. The candidate therapy is being developed for Cushing’s disease and congenital adrenal hyperplasia (CAH), both characterized by abnormally high levels of ACTH. In the case of Cushing’s disease, this is usually due to a tumor in the pituitary gland in the middle of the base of the brain. “ACTH…

You must be logged in to read/download the full post.